Letter
Medicine, General & Internal
Tawee Tanvetyanon
Summary: This article reports that neoadjuvant treatment with nivolumab does not impede the feasibility of lung cancer surgery, but some patients had their surgeries canceled due to disease progression after treatment, which is concerning as they could have been cured through surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Tigran Makunts, Ila M. Saunders, Isaac Cohen, Mengxing Li, Talar Moumedjian, Masara A. Issa, Keith Burkhart, Peter Lee, Sandip Pravin Patel, Ruben Abagyan
Summary: The study found a significant increase in reports of myocarditis in patients treated with immune checkpoint inhibitors, especially in combination therapies. Different combinations of therapies led to further increases in reporting odds ratios of myocarditis. Stratified analysis based on specific cancer types and treatment plans confirmed this trend.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhen-zhen Fan, Li-Juan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang, Xin-Ran Tang, Yu-Jie Zeng, Xinghua Pan, De-Hua Wu, Zhong-Yi Dong
Summary: This study finds that LKB1 mutation confers resistance to immune checkpoint blockade therapy in lung adenocarcinoma by impairing the trafficking and adhesion process of activated T cells and suppressing the expression of ICAM1. However, ectopic expression of ICAM1 in LKB1-deficient tumors promotes the activation and homing of CD8(+) T cells, restoring tumor-effector cell interaction and resensitizing tumors to immune checkpoint blockade. Moreover, CDK4/6 inhibitors can upregulate ICAM1 expression in LKB1-deficient cancer cells and enhance the anti-tumor immune response when used in combination with anti-PD-1 antibodies.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q. M. Chow, Marco Angelo Burgio, Javier de Castro Carpeno, Adam Pluzanski, Oscar Arrieta, Osvaldo Aren Frontera, Rita Chiari, Charles Butts, Joanna Wojcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, Miriam Alonso Garcia, David Waterhouse, Manuel Domine, Fabrice Barlesi, Scott Antonia, Markus Wohlleber, David E. Gerber, Grzegorz Czyzewicz, David R. Spigel, Lucio Crino, Wilfried Enst Erich Eberhardt, Ang Li, Sathiya Marimuthu, Julie Brahmer
Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Adam Lauko, Rupesh Kotecha, Addison Barnett, Hong Li, Vineeth Tatineni, Assad Ali, Pradnya Patil, Alireza M. Mohammadi, Samuel T. Chao, Erin S. Murphy, Lilyana Angelov, John H. Suh, Gene H. Barnett, Nathan A. Pennell, Manmeet S. Ahluwalia
Summary: This study found that patients with NSCLCBM who received ICIs had significantly improved overall survival compared to those who did not receive ICIs. In patients with KRAS mutations, the ICI-90 group had a higher one-year survival rate than those in the no-ICI group.
SCIENTIFIC REPORTS
(2021)
Review
Clinical Neurology
Pushpa Narayanaswami, Donald B. Sanders, Gil Wolfe, Michael Benatar, Gabriel Cea, Amelia Evoli, Nils Erik Gilhus, Isabel Illa, Nancy L. Kuntz, Janice Massey, Arthur Melms, Hiroyuki Murai, Michael Nicolle, Jacqueline Palace, David Richman, Jan Verschuuren
Summary: This study updated the 2016 formal consensus-based guidance for the management of myasthenia gravis, with updated recommendations on thymectomy and new recommendations on the use of rituximab, eculizumab, and methotrexate. The consensus guidance developed by international MG experts based on new evidence can provide direction for clinicians caring for MG patients worldwide.
Article
Oncology
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Katherine Minichiello, Liza C. Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highleyman, Vassiliki Papadimitrakopoulou, David R. Gandara, Karen Kelly, Roy S. Herbst
Summary: This randomized phase II trial demonstrated that the combination of ramucirumab and pembrolizumab significantly improved overall survival in patients with advanced non-small-cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy. The safety profile of this combination therapy was consistent with the known toxicities of both drugs.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Herve Pegliasco, Corentin Richard, Francois Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillere, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stephanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse
Summary: In addition to PD-L1 expression, biomarkers for predicting the response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. This study found that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI treatment in NSCLC patients, independent of PD-L1 expression and other factors. The relative abundance of Akk in the gut microbiome may serve as a potential biomarker for patient stratification.
Article
Oncology
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M. Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse, Solange Peters
Summary: This study evaluated the use of Pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC. The results showed that Pembrolizumab significantly improved disease-free survival in both the overall population and the PD-L1 TPS of 50% or greater population.
Review
Biochemistry & Molecular Biology
Terenzio Cosio, Filadelfo Coniglione, Valeria Flaminio, Roberta Gaziano, Deborah Coletta, Rosalba Petruccelli, Emi Dika, Luca Bianchi, Elena Campione
Summary: Immunotherapy in oncology is replacing traditional therapies due to its specific action and limited side effects. However, bacterial infections can still occur as side effects. This case report highlights the importance of considering lifestyle and cutaneous background before starting immunotherapy for cancer treatment, with a focus on pharmacogenomics and the possibility of modified skin microbiota predisposing to cutaneous infections in patients treated with PD-1 inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Kamya Sankar, Garth W. Strohbehn, Lili Zhao, Victoria Daniel, David Elliott, Nithya Ramnath, Michael D. Green
Summary: Increasing tumor PD-L1 expression is prognostic for progression-free survival (PFS) and overall survival (OS) among patients with stage III non-small cell lung cancer (NSCLC) treated with adjuvant durvalumab. Patients with PD-L1 expression < 1% may have limited benefit from adjuvant durvalumab.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Immunology
Fang Chen, Jinping Wang, Puli Zhang, Yu Zuo, Lifang Ye, Guochun Wang, Xiaoming Shu
Summary: This study demonstrates that DM-ILD patients with negative MSA/MAA have favorable long-term outcomes. Decreased baseline PaO2/FiO2 is identified as an independent prognostic factor for this group of patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Article
Oncology
Scott N. Gettinger, Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B. Leighl, Suresh S. Ramalingam, Susan S. Tavernier, Hui Yu, Joseph M. Unger, Katherine Minichiello, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara, Roy S. Herbst
Summary: In this study, it was found that adding ipilimumab to nivolumab did not improve outcomes in patients with advanced, pretreated, immune checkpoint inhibitor-naive squamous non-small cell lung cancer.
Article
Oncology
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen R. Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde
Summary: We present the 5-year clinical outcomes of neoadjuvant nivolumab in resectable non-small cell lung cancer, showing favorable recurrence-free survival (60%) and overall survival (80%) rates. Major pathological responses and tumor PD-L1 positivity are associated with improved recurrence-free survival. This study provides the longest follow-up data for neoadjuvant anti-PD-1 therapy in any cancer type.
CLINICAL CANCER RESEARCH
(2023)
Review
Medicine, General & Internal
Marcello Cottini, Carlo Lombardi, Giovanni Passalacqua, Diego Bagnasco, Alvise Berti, Pasquale Comberiati, Gianluca Imeri, Massimo Landi, Enrico Heffler
Summary: Asthma is a worldwide chronic disease in which small airways dysfunction (SAD) plays a significant role. SAD is associated with the severity, control, and exacerbation frequency of asthma, yet it is not adequately addressed in the Global Initiative for Asthma guidelines.
FRONTIERS IN MEDICINE
(2022)
Meeting Abstract
Rheumatology
D. Campaniello, E. Treppo, B. D'onofrio, G. Franchi, A. Berti, L. Iorio, R. Bortolotti, C. Montecucco, S. Monti, L. Quartuccio, A. Doria, F. Schiavon, R. Padoan.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Oncology
Michele Tomasi, Elena Caproni, Mattia Benedet, Ilaria Zanella, Sebastiano Giorgetta, Mattia Dalsass, Enrico Koenig, Assunta Gagliardi, Laura Fantappie, Alvise Berti, Silvia Tamburini, Lorenzo Croia, Gabriele Di Lascio, Erika Bellini, Silvia Valensin, Giada Licata, Guido Sebastiani, Francesco Dotta, Federica Armanini, Fabio Cumbo, Francesco Asnicar, Aitor Blanco-Miguez, Eliana Ruggiero, Nicola Segata, Guido Grandi, Alberto Grandi
Summary: A growing body of evidence supports the important role of the gut microbiome in cancer immunity, and it has been found that microbiome proteins can induce specific T cells, which can inhibit tumor growth. Furthermore, personalized mucosal cancer vaccines can be developed using engineered microbes and Outer Membrane Vesicles.
FRONTIERS IN ONCOLOGY
(2022)
Meeting Abstract
Critical Care Medicine
Karina A. Keogh, Alvise Berti, Garvan C. Kane
Review
Rheumatology
Goncalo Boleto, Alvise Berti, Peter A. Merkel, Sibel Zehra Aydin, Haner Direskeneli, Christian Dejaco, Leslie C. Hassett, Loreto Carmona, Sofia Ramiro, O. M. E. R. A. C. T. Vasculitis Working Grp OMERACT Vasculitis Working Grp
Summary: This study systematically reviewed the measurement properties of outcome instruments used in large-vessel vasculitis (LVV). Out of the 3534 articles identified, 13 met the criteria, addressing 12 instruments. The Indian Takayasu Clinical Activity Score (ITAS) and the Disease Extent Index-Takayasu (DEI-Tak) showed the most adequate measurement properties for disease activity/damage in TA, while specific instruments for GCA and validated patient-reported outcomes for both GCA and TA were lacking.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Clinical Neurology
Simon Licht-Mayer, Graham R. Campbell, Arpan R. Mehta, Katie McGill, Alex Symonds, Sarah Al-Azki, Gareth Pryce, Stephanie Zandee, Chao Zhao, Markus Kipp, Kenneth J. Smith, David Baker, Daniel Altmann, Stephen M. Anderton, Yolanda S. Kap, Jon D. Laman, A. Bert, Moses Rodriguez, Robin J. M. Franklin, Siddharthan Chandran, Hans Lassmann, Bruce D. Trapp, Don J. Mahad
Summary: This study identifies a consistent and robust phenomenon called axonal response of mitochondria to demyelination (ARMD) in experimental demyelination models, which is also observed in multiple sclerosis (MS). The increase in mitochondrial content within demyelinated axons is not always accompanied by a proportionate increase in complex IV activity, particularly in highly inflammatory models. The findings highlight the importance of complex IV activity and pave the way for the development of novel neuroprotective therapies.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
(2023)
Review
Rheumatology
Baptiste Chevet, Divi Cornec, Marta Casal Moura, Emilie Cornec-Le Gall, Fernando C. Fervenza, Kenneth J. Warrington, Ulrich Specks, Alvise Berti
Summary: ANCA-associated vasculitides (AAV) are rare, primary, systemic necrotizing small-vessel vasculitides. The most common types are granulomatosis with polyangiitis and microscopic polyangiitis. Risk factors for developing AAV include exposure to silica dust, farming, and chronic nasal Staphylococcus aureus infection. Diagnosis of AAV requires further investigation, including ANCA testing, and a structured clinical assessment. Treatment options vary depending on the severity of AAV and the patient's characteristics, with rituximab being favored as an effective option for both induction and maintenance of remission.
Article
Rheumatology
Alvise Berti, Fabiola Atzeni, Lorenzo Dagna, Stefano Del Giacco, Giacomo Emmi, Carlo Salvarani, Augusto Vaglio
Summary: Only a minority of EGPA patients can be weaned off glucocorticoids using conventional treatment strategies. Targeting the IL-5 pathway with biological agents has shown potential for treating EGPA, but the optimal candidates and dosing regimens are still unclear.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H. Schirmer, Alvise Berti, Daniel Blockmans, Maria C. Cid, Julia U. Holle, Nicole Hollinger, Omer Karadag, Andreas Kronbichler, Mark A. Little, Raashid A. Luqmani, Alfred Mahr, Peter A. Merkel, Aladdin J. Mohammad, Sara Monti, Chetan B. Mukhtyar, Jacek Musial, Fiona Price-Kuehne, Marten Segelmark, Y. K. Onno Teng, Benjamin Terrier, Gunnar Tomasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne
Summary: Since the publication of the EULAR recommendations for the management of AAV in 2016, several clinical trials have been conducted that have the potential to change clinical care. A systematic literature review and expert opinions were used to modify existing recommendations and create new ones. The recommendations provide updated guidance on AAV management.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Pharmacology & Pharmacy
Christian Pagnoux, Alvise Berti
Summary: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis with potentially lethal outcomes. Treatment options for EGPA have been adapted from other vasculitides, and monoclonal antibodies targeting various pathways, such as IL5 and B cells, have been investigated. This review provides an overview of published studies on EGPA treatments, including glucocorticoids, conventional immunosuppressants, anti-IL5 pathway agents, and potential future treatments. Expert opinion suggests that with advancements in pharmacotherapeutic management, the prognosis of EGPA has improved, and more targeted and safer treatments are available. However, further research and long-term data are needed to optimize treatment strategies for individual patients.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Rheumatology
Giacomo Emmi, Alessandra Bettiol, Elena Gelain, Ingeborg M. Bajema, Alvise Berti, Stella Burns, Maria C. Cid, Jan W. Cohen Tervaert, Vincent Cottin, Eugenia Durante, Julia U. Holle, Alfred D. Mahr, Marcos Martinez Del Pero, Chiara Marvisi, John Mills, Sergey Moiseev, Frank Moosig, Chetan Mukhtyar, Thomas Neumann, Iacopo Olivotto, Carlo Salvarani, Benjamin Terrier, Renato A. Sinico, Camille Taille, Benjamin Terrier, Nils Venhoff, George Bertsias, Loic Guillevin, David R. W. Jayne, Augusto Vaglio
Summary: This article presents the first Evidence-Based Guideline specifically for diagnosing and managing eosinophilic granulomatosis with polyangiitis (EGPA). The 16 statements and five overarching principles cover diagnosis, treatment, outcome, and follow-up of EGPA. These guidelines are intended to guide clinical practice and decision-making in EGPA, and are based on a multidisciplinary approach and expert opinion.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Marcello Cottini, Carlo Lombardi, Pasquale Comberiati, Massimo Landi, Alvise Berti, Laura Ventura
Summary: Small airway dysfunction (SAD) has a significant impact on asthma control in patients using SABA-only therapy, leading to increased severe exacerbations, higher use of SABA canisters, and poorly controlled asthma.
RESPIRATORY MEDICINE
(2023)
Article
Rheumatology
Advise Berti, Divi Cornec, Anisha B. Dua
Summary: GPA and MPA are ANCA-associated vasculitides that cause inflammation and necrosis of small blood vessels, leading to ischemia and organ damage.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
(2023)
Article
Respiratory System
Carlo Lombardi, Alvise Berti, Marcello Cottini, Elena Roca, Laura Ventura
Summary: The objective of this study was to investigate the role of the 6-minute walk test (6MWT) in severe asthma. The results showed that patients treated with mepolizumab demonstrated significant improvements in pulmonary function tests and clinical laboratory parameters. Additionally, the 6MWT distance showed significant positive correlations with asthma control test and asthma quality of life questionnaire.
Article
Rheumatology
A. Manfredi, G. Cassone, R. Izzo, G. Dallagiacoma, M. Felicetti, A. Cariddi, A. Berti, A. Giollo, C. Nannini, S. Bettio, S. Monti, E. Conticini, M. Govoni, L. Quartuccio, L. M. Argolini, S. Kaleci, G. Emmi, C. Dejaco, R. Padoan, L. Dagna, M. Rossini, F. Cantini, C. Montecucco, B. Frediani, S. De Vita, R. Caporali, F. Muratore, M. Sebastiani, C. Salvarani
Summary: This study describes the presence of interstitial lung disease (ILD) in antineutrophil cytoplasmic antibodies-associated vasculitides (AAV). It found that non-specific interstitial pneumonia (NSIP) was the most common ILD pattern, observed in c-ANCA positive patients. The study also highlights the early complication of ILD in AAV and emphasizes the importance of early diagnosis by both pulmonologists and rheumatologists.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
